Electra City Tower
58 Harakevet St.
Tel Aviv
6777016
Misha Gitterman
Misha is a partner in the firm's Capital Markets Department.
Adv. Misha Gitterman has over 30 years of experience providing representation in corporate financing transactions, mergers and acquisitions, and investment transactions, both local and international.
Misha represents private equity funds, venture capital funds, and institutional investors in a wide range of complex transactions.
In addition, Misha represents clients operating in a variety of business areas. He advises on all aspects of their business and corporate activities, with a special emphasis on guiding startups throughout the stages of their development, including and especially with regard to raising private and public funding.
Misha also has special expertise in representing investors and technology ventures for the elderly. Along with his rich legal experience, Misha worked for many years as a senior manager in an investment and public holding company and as a director in private and public companies. Misha is a member of the National Board of Directors, elected by the Government Companies Authority.
Prominent legal directory The Legal 500 ranks Misha in the Banking & Finance practice area.
Education:
Tel Aviv University, LL.B., 1995
Tel Aviv University, B.A. in Economics, 1995
Admission:
Israel Bar Association, 1996
Insights & News - Misha Gitterman:
Israel Chapter of The Legal 500: Shareholder Activism Guide 2025
The Legal 500 has, for the first time, published a comprehensive guide on shareholder rights, activist investing, and corporate governance regulation. Adv. Micky Barnea and Adv. Misha Gitterman from our firm provided the chapter covering the local legal framework in Israel.
Barnea: Representing Syremis in a USD 165 Million Investment Round
Adv. Michael Barnea, Adv. Misha Gitterman, and Adv. Tal Freilich represented Syremis Therapeutics, a spin-off of Clexio Biosciences, in the completion of a USD 165 million Series A financing round co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, Google Ventures, and QVT.